Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.

Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, Conley RR.

Curr Med Res Opin. 2011 Apr;27(4):713-30. doi: 10.1185/03007995.2011.554533. Review.

PMID:
21265593
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
4.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
5.

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.

Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD.

J Med Econ. 2012;15(3):531-47. doi: 10.3111/13696998.2012.662923.

PMID:
22304338
6.

Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.

Einarson TR, Vicente C, Zilbershtein R, Piwko C, Bø CN, Pudas H, Jensen R, Hemels ME.

Nord J Psychiatry. 2014 Aug;68(6):416-27. doi: 10.3109/08039488.2013.852243.

PMID:
24274837
7.

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.

Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.

Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x.

8.

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, Culler SD.

Cost Eff Resour Alloc. 2009 Apr 7;7:4. doi: 10.1186/1478-7547-7-4.

9.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
10.

Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.

Tempest M, Sapin C, Beillat M, Robinson P, Treur M.

J Ment Health Policy Econ. 2015 Dec;18(4):185-200.

PMID:
26729007
11.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
12.

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.

Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A.

J Med Econ. 2012;15(5):844-61. doi: 10.3111/13696998.2012.681531.

PMID:
22458756
13.

Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.

Einarson TR, Pudas H, Zilbershtein R, Jensen R, Vicente C, Piwko C, Hemels ME.

J Med Econ. 2013 Sep;16(9):1096-105. doi: 10.3111/13696998.2013.823869. Erratum in: J Med Econ. 2013 Nov;16(11):1366.

PMID:
23844621
14.

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.

Dilla T, Möller J, O'Donohoe P, Álvarez M, Sacristán JA, Happich M, Tockhorn A.

BMC Psychiatry. 2014 Dec 2;14:298. doi: 10.1186/s12888-014-0298-4.

15.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group..

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
16.

Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.

Einarson TR, Pudas H, Goswami P, van Impe K, Bereza BG.

J Med Econ. 2016;19(2):111-20. doi: 10.3111/13696998.2015.1100115.

PMID:
26414966
17.

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .

Davies A, Vardeva K, Loze JY, L'italien GJ, Sennfalt K, Baardewijk Mv.

Curr Med Res Opin. 2008 Nov;24(11):3275-85. doi: 10.1185/03007990802507547 .

PMID:
18947458
18.

Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

Zeidler J, Mahlich J, Greiner W, Heres S.

Appl Health Econ Health Policy. 2013 Oct;11(5):509-21. doi: 10.1007/s40258-013-0050-0. Erratum in: Appl Health Econ Health Policy. 2013 Dec;11(6):689.

PMID:
23975630
19.
20.

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.

Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.

Psychiatry Clin Neurosci. 2005 Aug;59(4):385-94. Erratum in: Psychiatry Clin Neurosci. 2005 Oct;59(5):625-6. Tarn, Yeng Hui [corrected to Tarn, Yen-Huei].

Items per page

Supplemental Content

Support Center